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Abstract (110/250 words) 
Transcatheter aortic valve implantation is now accepted as a standard mode of treatment for 
an increasingly large population of patients with severe aortic stenosis.  With the availability 
of this technique, echocardiographers need to be familiar with the imaging characteristics that 
can help to identify which patients are best suited to conventional surgery or transcatheter 
aortic valve implantation, and what parameters need to be measured.  This article highlights 
the major features that should be assessed during transthoracic echocardiography prior to 
presentation of the patient to the ‘Heart Team’.  In addition, the article summarises the 
aspects to be considered on echocardiography during follow-up assessment after successful 
implantation of a transcatheter aortic valve. 
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Transcatheter Aortic Valve Implantation (TAVI) is now firmly established as a treatment for 
symptomatic aortic stenosis (AS), in patients who cannot undergo or who are considered too 
high risk for conventional surgical aortic valve replacement (SAVR).  Since the advent of the 
PARTNER trial [1, 2], the adoption of TAVI has increased exponentially worldwide as a 
method of treating symptomatic AS [3].  With further trials enrolling patients at intermediate 
as well as high risk [4], the indications for TAVI are set to grow and the demand for pre-
procedural assessment will increase (Figure 1). 
 
European and American guidelines highlight the central role of the multi-disciplinary (Heart) 
team when deciding on appropriate intervention in AS [5, 6].  This team is tasked with the 
selection of those who would benefit most from SAVR or TAVI, and those who should not 
undergo intervention on the basis that they would not benefit either in terms of symptoms 
(minimum expected gain more than one NYHA class) or life expectancy (minimum expected 
survival > 1 year following a successful procedure) [6].  While a large and growing body of 
literature has confirmed both survival advantage and symptom benefit compared to medical 
therapy with TAVI [1, 2], one in four patients report only limited improvement either in 
quality of life or functional status [7] and almost one in five do not live beyond the first year 
following implantation [3].  Scoring systems such as the Society of Thoracic Surgeons Risk 
Calculator or Euroscore fail to take into account patient specific factors including co-
morbidity, major organ system compromise or patient frailty.  A number of important factors 
however, may be identified by a comprehensive transthoracic echocardiogram (TTE) to 
inform decision-making for the patient and the aim of this article is to highlight those that 
should be emphasised in any report.  There is recent evidence to suggest regular follow-up by 
TTE following implantation is important and this article will outline what should be assessed 
following TAVI. 
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Pre-Procedural Transthoracic Echocardiography 
 
Aortic Stenosis (AS) Severity 
The leading priority for the Heart Team is to ensure that each patient has a confirmed 
diagnosis of severe AS meeting class 1 indications for intervention [5].  In the absence of 
symptoms, there is no significant increase in age-adjusted mortality with mild, moderate or 
severe AS [8] as compared to a combined procedural and 30-day mortality rate of 6% with 
TAVI [3].  Therefore, confirmation that AS is severe and that symptoms are due to valve 
disease remains critical.  One major and recurrent problem is inconsistency in grading 
severity of AS by TTE when using the standard haemodynamic parameters recommended for 
evaluation of severity, comprising maximal velocity, mean gradient and aortic valve area 
(AVA) [9, 10].  This inconsistency can be attributed to several factors: 
i) Measurement of maximum velocity and highest mean gradient across the stenotic 
valve - This demands that multiple measures are made from different acoustic windows.  In a 
recent study of 100 consecutive patients undergoing TTE for severe AS within a single 
department, the right parasternal window was superior for identifying maximal velocity 
(Figure 2) [11].  When sampling maximal velocity from only the apical window, nearly a 
quarter of patients were misclassified with two-thirds under-estimated as moderate AS, and a 
third with paradoxical low flow rather than normal flow severe AS.  One of the factors 
thought to influence the non-apical location of the maximal peak velocity may be increasing 
angulation of the ventricular-aortic junction with advancing age. 
ii) Variability in acquiring the data and variability in measuring the data - Velocity 
measurements have a very low inter- and intra-observer measurement variability once 
acquired but left ventricular outflow tract (LVOT) dimension measures may vary between 5-
9% between echocardiographers even using the same image [12].  Even when reproducibility 
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is optimised between echocardiographers, the LVOT is elliptical in many patients with AS 
and the 2D measure used for calculation of the area on 2D TTE is often the shortest 
dimension, such that the continuity equation may still under-estimate the AVA [13]. The 
variability is further accentuated in the hypertensive patient, in whom the LVOT orifice 
becomes progressively more elliptical, leading to under-estimation of stroke volume and 
AVA [14].  This means that 3D TTE should be used when technically possible to measure the 
LVOT area, since this improves accuracy in grading (Figure 3) [15].  Stroke volume derived 
from 3D LV datasets can also be used as an internal validator for accuracy.  The use of the 
Doppler Velocity Index (DVI), a ratio of the velocity time integral in the LVOTvti/AVvti, 
avoids the need for LVOT measurements altogether overcoming some of these inaccuracies.  
A partition value below 0.25 has been shown to identify a group of patients with a high rate 
of valve-related events, including death [16]. 
iii) Discrepancy in measurement of AS severity relative to a low aortic valve area (AVA 
<1cm2) - typically with a low maximal velocity or mean gradient (Vmax<4.0m/s; mean 
<40mmHg).  After exclusion of measurement inaccuracy, one of the main reasons for this 
presentation is LV dysfunction (LVEF <40%).  Whilst exercise stress echocardiography has 
much to add to the assessment of aortic stenosis in patients with preserved LV function, low 
dose dobutamine stress echocardiography (to a maximum of 20mcg) is required in the 
assessment of AS severity and operative risk stratification in AS with impaired LV and low 
gradient.  Confirmation that AS is severe requires demonstration of a maximal velocity above 
4m/s or mean gradient above 40mmHg at any stage with AVA below 1.0cm2 at any flow rate 
[17].  This is important not only in identifying patients who would benefit from AVR but also 
selecting out those patients at higher peri-operative risk with SAVR (LV stroke volume or EF 
improvement <25%).  The latter does not apply to TAVI, since LV impairment at time of 
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procedure does not affect peri-procedural outcomes from percutaneous intervention but is a 
major factor in determining surgical survival [18]. 
 
The other main reason for a low maximal velocity or mean gradient, relative to a low aortic 
valve area (AVAi<0.6cm2/m2) is the presence of a low stroke volume ( <35mL/m2) in the 
context of preserved LV function (LVEF>40%).  Sub-group analysis of the PARTNER data 
clearly demonstrated improved survival in patients with so-called low gradient, low flow, 
normal ejection fraction (LF LG nEF) severe AS following TAVI compared to medical 
therapy at 2 years (56.5% vs 76.9%) [19].  Given the limitations in measurement of LVOT-
derived stroke volume on Doppler however, this diagnosis can be problematic and requires a 
systematic approach.  Firstly, visual assessment of the 2D appearance and mobility of the 
aortic valve is important with severe AS being unlikely if a cusp tip opens well or one leaflet 
remains mobile.  A small study suggested this had high specificity for the severity of aortic 
stenosis [20].  Secondly, grading extent of valve calcification is an important factor in 
predicting outcome in AS [21], although visual estimation on 2D has high inter-observer 
variability (Figure 4) [20].  Thirdly, concomitant valve lesions which may reduce transaortic 
flow need to be identified – particularly severe mitral valve disease.  Finally, other supporting 
characteristics of patients with true LF LG nEF AS should be highlighted in the echo report, 
including small LV cavity size [22], concentric remodelling with increased LV mass [23], 
and high valvulo-arterial impedance (Zva>5.5mmHg/mL/m2) (Figure 5) [24].  A simple 
additional marker of severity is M-mode-derived mitral annular plane systolic excursion, with 
a cut-off below 9mm having high accuracy in separating out those with low gradient, severe 
AS from those with low gradient, moderate AS [25].  Where these additional features are 
absent, imaging should be repeated to minimise measurement error and consideration given 
to the possibility that indexed AVA may be low as a result of a very low body surface area.  
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It should also be remembered that there are inconsistencies between Gorlin formula derived 
valve areas and mean gradients derived from Doppler used to generate guideline criteria 
partition values.  Theoretical modelling has shown that with a normal flow rate and an EOA 
of 1cm2 that a mean gradient would be expected to be closer to 30mmHg than 40mmHg.  
This means that the presence of LG normal flow nEF AS confers a better prognosis than low 
flow [26]. 
Combined AS and aortic regurgitation can be difficult to assess when both are in the 
moderate range, although the peak velocity across the aortic valve still holds prognostic 
weight in this situation [27]. Identifying AR can be an important factor in determining 
management, for example, the presence of severe AR may prohibit palliative balloon 
valvuloplasty and would likely modify its use during the TAVI procedure itself. 
 
Aortic Valve Morphology 
There are important features of the aortic valve complex that deserve mention in the 
transthoracic report. Firstly, the diastolic sinus of Valsalva diameter and height, diastolic 
diameter of the sinotubular junction, as well as the systolic left main coronary artery position 
may influence the size of TAVI selected as well as decisions about valve placement, although 
some may be better assessed on TOE [28].  Secondly, consideration should be given to 
symmetry of opening of the aortic valve, in particular whether this is bicuspid or tricuspid. 
Congenital bicuspid AS presents earlier than degenerative disease and may affect the decision 
whether to proceed with surgery or TAVI. Although TAVI can be performed effectively in 
patients with a bicuspid valve, there is a higher incidence and greater severity of aortic 
regurgitation post procedure, as frequently as 28% of cases [29]. Thirdly, calcification 
beyond the leaflets themselves is predictive of post-procedural AR and should be noted, 
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particularly if there are ectopic deposits in the LVOT, sinus or proximal root [30]. Calcific 
deposits around the coronary ostia increase the risk of coronary obstruction, while 
calcification within the aortic complex may increase risk of annular rupture, root perforation, 
aortic wall haematoma and dissection [31].  Finally, together with ectopic LVOT 
calcification, severe basal septal hypertrophy may influence the choice of prosthesis, 
although the latter is common in the elderly hypertensive patient.  Balloon expandable valves 
have a lower profile compared to self-expanding valves; but the positioning of both can be 
influenced by a severely hypertrophied basal septum. 
 
Mitral Regurgitation 
Community studies have demonstrated that mitral regurgitation (MR) is the most common 
valve lesion, with prevalence increasing with age [32].  The presentation of patients to the 
Heart Team with both severe AS and mitral regurgitation is therefore common, and has been 
reported in up to 74% elderly candidates undergoing SAVR or TAVI [33].  Accurate 
quantification of MR on pre-procedural TTE is important.  Firstly, the presence of moderate-
severe MR will lower maximal velocity and mean gradient across a stenosed aortic valve, 
which may lead to misclassification.  Secondly, recent data have highlighted the adverse 
morbidity and mortality associated with residual moderate or severe MR following isolated 
SAVR [34].  Several recent studies have considered the patient referred for TAVI who also 
has moderate-severe MR and these have focussed on two questions: firstly, does TAVI lead 
to change in severity of MR; secondly, if moderate-severe MR is left untreated, what impact 
does this have on early and late outcome?  In contemporary TAVI cohorts, the incidence of 
moderate-severe MR appears to be around 15%, equally divided between primary (organic) 
and secondary (functional) aetiologies [33].  In a recent meta-analysis of 9 studies including 
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over 8000 subjects, moderate MR was present at baseline in 386 (5%) and severe in 135 (2%) 
patients.  After TAVI, moderate MR improved in 48.2%, remained the same in 48.7% and 
deteriorated in 3.1%, while in severe MR it improved in 57% and remained unchanged in the 
remainder [35].  While MR may therefore improve following TAVI, the same meta-analysis 
also highlighted that those with residual MR post-TAVI are exposed to a similar increase in 
mortality as following isolated SAVR (30-day mortality: HR 1.49, 95% CI 1.16 - 1.92; 1-year 
mortality HR 1.32, 95% CI 1.12 - 1.55).  Though two earlier studies suggested outcomes 
were better with functional rather than primary organic MR [36, 37], these findings were not 
confirmed in a recent meta-analysis which showed outcomes were influenced by severity of 
MR but not aetiology [38].  It is therefore imperative that any pre-procedural echo identify 
both the presence and quantify severity of MR to optimise discussion of the patient in the 
Heart Team meeting (Figure 6). 
 
Left Ventricular Function 
The prognosis of patients with symptomatic and asymptomatic severe AS is worse when 
associated with LV dysfunction.  Even at extremes of left ventricular (LV) dysfunction 
(ejection fraction <20%), patients who survive SAVR have a much better prognosis than 
those managed medically [39, 40].  In patients considered unfit for SAVR undergoing TAVI, 
there were no differences in 30-day or 1-year survival between those with LVEF above or 
below 50% (or in a smaller sub-group with LVEF<35%), and survival was higher than in 
patients treated medically [18].  Even patients with severely impaired LV function should 
therefore be referred for discussion by the Heart Team, with current data suggesting that such 
patients may fare better with TAVI than SAVR.  Pre-procedural LV dysfunction did not 
affect 30-day mortality in the inoperable cohort, a finding confirmed in the high risk cohort of 
PARTNER (although those with LVEF <20% were excluded) [41].  This contrasts with the 
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increased 30-day mortality following SAVR, particularly in those with prior myocardial 
infarction [42].  Interestingly in the PARTNER B cohort, improvement in LVEF by >10% 
after TAVI was observed in half of patients considered unsuitable for SAVR and was more 
likely to occur in those with smaller pre-procedural LV internal dimensions and less mitral 
regurgitation [18].  While improvement in LVEF does not appear to produce a survival 
benefit in inoperable patients, failure of LVEF to improve carries adverse prognostic 
significance in high risk patients at 1 year [41]. 
 
Right Ventricular Function and Pulmonary Hypertension 
Pulmonary hypertension (PH) occurs in 25% of patients with severe AS and is more common 
in those with low LVEF, evidence of high filling pressure and moderate-severe MR [43, 44].  
Patients with high pulmonary artery pressure (PAP) have a perioperative mortality as high as 
35% with SAVR and is a major reason for “surgical turndown” [45].  Registry data have 
demonstrated that PH (defined on TTE by systolic PAP >40mmHg) does not adversely affect 
procedural success, early complication rate or 30-day mortality following TAVI but does 
increase 1-year mortality to 22% (28%>60mmHg sPAP) [46].  Despite the presence of high 
sPAP, patients continue to benefit symptomatically from TAVI and in some, PAP falls during 
follow-up.  These echo data were supported in a retrospective analysis of 2180 patients 
undergoing invasive catheter studies from PARTNER A and the PARTNER registry, in 
which 1 year mortality was higher (25%) in those with moderate/severe PHT (mPAP 
>35mmHg) compared with those with no PHT (18%, mPAP <25mmHg) [47].  In the latter 
study, risk stratification was further improved with clinical variables, including 6-minute 
walk test, oxygen-dependent lung disease and impaired renal function but the only echo-
derived haemodynamic parameter of use was lower mean gradient. 
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Tricuspid Regurgitation 
TTE in patients with severe aortic stenosis requires a complete study of the tricuspid valve 
and right ventricle.  Moderate or severe functional tricuspid regurgitation (TR) is present in 
about 5% patients referred for SAVR for severe AS (Figure 7) [48].  In these patients, 
residual TR following surgery does not improve in half of all patients, may be progressive 
and is associated with higher late mortality [49].  In patients following TAVI, registry data 
suggest that moderate or severe TR is more common (15%) and does not improve in the 
majority of patients following implantation [50].  Furthermore, TR was associated with a 
doubling of all-cause mortality at 2 years, an increase in risk that was found to be higher in an 
analysis of 542 patients from the inoperable PARTNER cohort [51].  In this group, 
randomised to TAVI or medical therapy, mortality at 1 year was 32.6% with moderate TR 
and 61.1% in those with severe TR on pre-procedural TTE, an increase in risk that was more 
marked in those with only mild or no mitral regurgitation.  Both right atrial dilatation and RV 
dysfunction were associated with mortality but the association with outcome and RV 
dysfunction was lost on a multi-variate model.  When assessing potential benefit from TAVI, 
the TTE needs to be reviewed for right atrial size from the apical four-chamber view, basal 
and mid right ventricular dimension, and RV function based on fractional area change [52].  
The tricuspid valve needs to be assessed for severity of TR, aetiology and mechanism, with 
calculation of sPAP (Table 1). 
 
Role of Pre- and Peri-Procedural Transoesophageal Echocardiography 
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Transoesophageal echocardiography (TOE) has traditionally been used as an integral part of 
pre-screening patients under consideration for TAVI and peri-procedurally to assess the 
degree of paravalular regurgitation and to detect complications (eg pericardial effusion) [28, 
53].  Although most of the patients within the PARTNER series of trials were treated with the 
assistance of intraprocedural TOE, recent data have suggested that TOE may not be necessary 
for safe placement of the valve or monitoring during TAVI [54, 55].  One barrier to universal 
intraprocedural TOE has been the need for general anaesthesia (GA) and a purported increase 
in risk associated with general anaesthesia in an elderly population with multiple co-
morbidities. Recent studies have shown similar safety and efficacy of conscious sedation 
(CS) compared to general anaesthesia [56], while others have demonstrated a benefit with CS 
in terms of reduced length of stay and lower cost [57].  One issue that remains to be decided 
is the impact of intraprocedural TOE on paravalvular regurgitation post TAVI, which has 
been associated with increased 1 year mortality [3].  The FRANCE 2 registry compared 
clinical outcomes for GA (n=1377) and CS (n=949), and showed a higher incidence of 
paravalvar leak > mild in the CS group (15.0% versus 19.1%; P=0.015) in whom TOE use 
was considerably less frequent (76.3% versus 16.9%; P<0.001) [58].  Longer term follow up 
is required to determine whether this difference has clinical consequence.  While the role for 
intra-procedural TOE remains hotly debated, there is no question that the frequency of TOE 
during the TAVI procedure itself has declined.  
 
In our centre, TOE is used pre-procedurally to clarify severity of aortic stenosis where this is 
uncertain on TTE and when TTE is inadequate to provide accurate data on LV size and 
function, presence and severity of mitral regurgitation, RV size and function, pulmonary 
pressure and presence and severity of tricuspid regurgitation as outlined. In many centres 
however, TOE is performed routinely as part of the pre-procedural assessment of the patient 
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prior to TAVI and is vital in those centres that do not use alternative imaging modalities such 
as computed tomography to measure the annulus for valve sizing. There are a number of 
other published articles on the relative merits of TOE compared to other imaging modalities 
in measuring annulus size, extent of calcification and prediction of post-procedural outcomes 
that will not be discussed in this article [28]. 
 
Post-Procedure TTE 
Data from the UK TAVI registry shows that over 80% of patients survive to 12 months and 
more than a third will be alive at 6 years, a figure likely to improve with advances in 
techniques and equipment [3].  Consensus agreement for echocardiographic assessment 
following discharge includes a baseline study at 30 days, at 1 year and annually thereafter – 
though supportive evidence for optimal frequency is lacking [45] (Table 2). 
 
Post-procedural AR remains a problem following TAVI, and though platform designs evolve 
with the main aim of reducing this outcome, UK TAVI data have shown that the incidence 
has not changed significantly and remains an important predictor of outcome (incidence of 
moderate or severe AR approximately 14%) [3]. AR post TAVI is almost universally 
paravalvular in origin and can be difficult to assess on TTE, partly due to acoustic shadowing 
from the valve stent, contributing to significant variability in grading (Figure 8) [59]. Recent 
guidance has been published to both illustrate the complexities of assessment and 
inconsistencies of grading, as well as provide a framework for its assessment [60].  It is 
suggested that the echocardiographers should use 5 grades of severity (mild, mild-moderate, 
moderate, moderate-severe, severe) with a view to increasing flexibility while over time, 
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improving accuracy and reproducibility. A multi-parametric and multimodality approach 
should be used, with the key features including: structural appearances of the THV stent, 
features of the AR jet (number, jet path and vena contracta), jet width as percentage of 
LVOT, and circumferential extent of the jet relative to the annulus. As yet, this grading 
system needs to be validated both against other imaging modalities and with outcome data. It 
is also important to remember that the presence of AR results in increased maximal forward 
velocity and mean gradient through the implanted TAVI, which must be taken into 
consideration if stenosis or obstruction is a possibility in follow-up. 
 
Recent evidence has emphasised the importance of the baseline study in which the 
haemodynamic parameters of the newly implanted TAVI valve are measured, including 
maximal velocity, mean gradient, effective orifice area and DVI.  Although early TAVI 
thrombus is uncommon [61], late valve thrombosis at a median of 6 months that cannot be 
visualised using TTE has been identified only through change in haemodynamic parameters, 
with explanted valves clearly demonstrating thrombus within the stent structure (Figure 9) 
[62].  It is important when making such measures to ensure pulsed wave Doppler 
interrogation is performed proximal to the stent of the prosthetic valve (pre-stent) rather than 
proximal to the leaflets (in-stent), since the latter can result in underestimation of the 
effective orifice area and over-diagnosis of prosthetic valve dysfunction and prosthesis 
mismatch [63].  Though early reports have come from CT based studies, analysis of 
bioprosthetic valve failure suggests that > 50% increase in mean gradient from baseline over 
5 years of follow up is an important predictor of valve thrombosis [64].  
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Four other distinct causes of TAVI failure have been identified, including device migration, 
structural valve failure, compression and prosthetic valve endocarditis.  Device migration, 
defined as ‘late’ when occurring greater than one hour post procedure, accounts for around 
10% of the total number of device embolisations [65].  Cases have been reported up to a year 
post procedure and occur more commonly in balloon expandable valves (83%) [66].  Most 
are retrograde into the LV outflow tract and are associated with rapid haemodynamic 
collapse, although cases have been reported on identification with TTE alone.  Risk factors 
for embolization include low valve implant within the LV, absence of calcification to act as 
an anchor and basal septal bulge leading to loss of apposition.  Valve stability should be 
scrutinised with reference to the baseline study to ensure prosthetic position is maintained. 
 
Structural valve failure with TAVI has been described rarely.  Mylotte et al identified 13 
cases occurring within 5 years follow-up and sharing a common aetiology to surgical 
bioprosthetic valve failure: pannus formation, leaflet degeneration and calcification, and 
rarely leaflet tear [66].  On TTE, these complications present with unexpected valvar stenosis, 
regurgitation or combined lesions.  Mylotte et al also identified 7 cases of TAVI 
compression, only with balloon expandable valves, and only on post mortem analysis.  In 
each of these cases, there was deformation of the stainless steel or cobalt-chromium stent, 
possibly as a result of chest wall compression during cardiopulmonary resuscitation.  This 
mandates repeat TTE for any patient resuscitated with CPR following TAVI implantation. 
 
A large multi-centre registry reported the incidence of infective endocarditis (IE) at one year 
following TAVI to be 0.5%, with the median time from implantation 6 months [67].  The 
most frequent causal organisms were typical (81.8%), including coagulase negative 
staphylococci, staphylococcus aureus and enterococci in similar proportions.  Orotracheal 
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intubation and the self-expanding Corevalve system were both associated with IE.  
Vegetations were identified in 77.4% of cases on echocardiography, though it is not clear the 
proportion of these that were identifiable on TTE.  Vegetations were identified on the valve 
leaflets, stent frame and mitral valve in 39.6%, 17% and 20.7% respectively. 
 
Conclusion 
Transcatheter aortic valve implantation is now accepted as a standard mode of treatment for 
an increasingly large population of patients with symptomatic severe AS.  With the 
availability of this technique, echocardiographers will need to be familiar with the imaging 
characteristics of patients that are best suited to conventional surgery or TAVI, and what 
parameters need to be assessed.  Whilst there are clinical factors that will heavily influence 
patient selection and outcomes; echocardiography plays an essential role in confirming the 
diagnosis of severe aortic stenosis as well as identifying factors that influence 1 year 
mortality, including aetiology and severity of MR, LV function, TR, RV dysfunction and 
pulmonary hypertension.  TTE should then be repeated within 30 days of the procedure, to 
establish baseline parameters for follow-up including maximal velocity, mean gradient, valve 
area, position and competence of valve. 
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